Marc T Goodman1, Mona Saraiya2, Trevor D Thompson3, Martin Steinau4, Brenda Y Hernandez5, Charles F Lynch6, Christopher W Lyu7, Edward J Wilkinson8, Thomas Tucker9, Glenn Copeland10, Edward S Peters11, Sean Altekruse12, Elizabeth R Unger4. 1. Cancer Prevention and Control Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: marc.goodman@cshs.org. 2. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: msaraiya@cdc.gov. 3. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 5. University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA. 6. Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA, USA. 7. Battelle Memorial Institute, Durham, NC, USA. 8. Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA. 9. Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY, USA. 10. Michigan Department of Community Health, Lansing, MI, USA. 11. Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA. 12. Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA.
Abstract
BACKGROUND: The presence of human papillomavirus (HPV) DNA in oropharyngeal squamous cell cancer (OPSCC) tissue appears to be a strong predictor of improved prognosis, but this observation has not been explored in a population-based sample with generalisable findings. METHODS: Follow-up data from a large sample of OPSCC patients identified through six population-based cancer registries in the United States of America (USA) were used to characterise the association of tumour HPV status with survival. RESULTS: HPV DNA was detected in tumour tissue from 71% (378 in 529) of the OPSCC patients. A total of 65% of patients with HPV16-associated tumours survived 5 years compared to 46% of patients with other HPV types and 28% of patients with HPV-negative tumours (p log-rank test <0.0001). The OPSCC patients with detectable HPV16 DNA had a 62% reduced hazard of death at 5 years, and patients with other HPV types had a 42% reduced hazard of death at 5 years compared to HPV-negative patients. Compared to non-Hispanic Whites, Blacks with OPSCC had a 2.6-fold greater risk of death at 5 years after adjustment for HPV status and other prognostic variables. Both surgery and radiation therapy were associated with a reduced 5-year risk of death, but no evidence was found for an interaction between HPV status and radiotherapy or surgery on survival time. CONCLUSIONS: Data from this US study suggest that HPV16-positive OPSCC patients survive longer than HPV-negative patients regardless of treatment, highlighting the prognostic importance of HPV status for this malignancy. Optimal treatment regimens for OPSCC could be tailored to each patient's HPV status and prognostic profile.
BACKGROUND: The presence of human papillomavirus (HPV) DNA in oropharyngeal squamous cell cancer (OPSCC) tissue appears to be a strong predictor of improved prognosis, but this observation has not been explored in a population-based sample with generalisable findings. METHODS: Follow-up data from a large sample of OPSCC patients identified through six population-based cancer registries in the United States of America (USA) were used to characterise the association of tumour HPV status with survival. RESULTS:HPV DNA was detected in tumour tissue from 71% (378 in 529) of the OPSCC patients. A total of 65% of patients with HPV16-associated tumours survived 5 years compared to 46% of patients with other HPV types and 28% of patients with HPV-negative tumours (p log-rank test <0.0001). The OPSCC patients with detectable HPV16 DNA had a 62% reduced hazard of death at 5 years, and patients with other HPV types had a 42% reduced hazard of death at 5 years compared to HPV-negative patients. Compared to non-Hispanic Whites, Blacks with OPSCC had a 2.6-fold greater risk of death at 5 years after adjustment for HPV status and other prognostic variables. Both surgery and radiation therapy were associated with a reduced 5-year risk of death, but no evidence was found for an interaction between HPV status and radiotherapy or surgery on survival time. CONCLUSIONS: Data from this US study suggest that HPV16-positive OPSCC patients survive longer than HPV-negative patients regardless of treatment, highlighting the prognostic importance of HPV status for this malignancy. Optimal treatment regimens for OPSCC could be tailored to each patient's HPV status and prognostic profile.
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Niklas Reimers; Hans U Kasper; Soenke J Weissenborn; Hartmut Stützer; Simon F Preuss; Thomas K Hoffmann; Ernst Jan M Speel; Hans P Dienes; Herbert J Pfister; Orlando Guntinas-Lichius; Jens P Klussmann Journal: Int J Cancer Date: 2007-04-15 Impact factor: 7.396
Authors: Martin Steinau; Juanita M Onyekwuluje; Mariela Z Scarbrough; Elizabeth R Unger; Joakim Dillner; Tiequn Zhou Journal: J Clin Microbiol Date: 2012-02-22 Impact factor: 5.948
Authors: Elaine M Smith; Linda M Rubenstein; Henry Hoffman; Thomas H Haugen; Lubomir P Turek Journal: Infect Agent Cancer Date: 2010-02-11 Impact factor: 2.965
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Justine M Ritchie; Elaine M Smith; Kurt F Summersgill; Henry T Hoffman; Donghong Wang; Jens P Klussmann; Lubomir P Turek; Thomas H Haugen Journal: Int J Cancer Date: 2003-04-10 Impact factor: 7.396
Authors: Martin Steinau; Mona Saraiya; Marc T Goodman; Edward S Peters; Meg Watson; Jennifer L Cleveland; Charles F Lynch; Edward J Wilkinson; Brenda Y Hernandez; Glen Copeland; Maria S Saber; Claudia Hopenhayn; Youjie Huang; Wendy Cozen; Christopher Lyu; Elizabeth R Unger Journal: Emerg Infect Dis Date: 2014-05 Impact factor: 6.883
Authors: Mererid Evans; Robert Newcombe; Alison Fiander; James Powell; Martin Rolles; Selvam Thavaraj; Max Robinson; Ned Powell Journal: BMC Cancer Date: 2013-05-01 Impact factor: 4.430
Authors: Angela L Mazul; Nidia Rodriguez-Ormaza; James M Taylor; Dipan D Desai; Paul Brennan; Devasena Anantharaman; Tarik Gheit; Massimo Tommasino; Behnoush Abedi-Ardekani; Andrew F Olshan; Jose P Zevallos Journal: Oral Oncol Date: 2016-09-06 Impact factor: 5.337
Authors: Hilda Razzaghi; Mona Saraiya; Trevor D Thompson; S Jane Henley; Laura Viens; Reda Wilson Journal: Cancer Date: 2017-11-06 Impact factor: 6.860
Authors: Carole Fakhry; Tim Waterboer; William H Westra; Lisa M Rooper; Melina Windon; Tanya Troy; Wayne Koch; Christine G Gourin; Noemi Bender; Siddhartha Yavvari; Ana P Kiess; Brett A Miles; William R Ryan; Patrick K Ha; David W Eisele; Gypsyamber D'Souza Journal: Oral Oncol Date: 2019-12-24 Impact factor: 5.337
Authors: Linda X Yin; Gypsyamber D'Souza; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni M Rettig; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; David W Eisele; Carole Fakhry Journal: Laryngoscope Date: 2018-03-14 Impact factor: 3.325
Authors: W Quinn O'Neill; Jay Wasman; Jason Thuener; Kate Chatfield-Reed; Lizabeth Lukesic; Ravi Kyasram; John Shanahan; Blake Szelesety; Brandon Vu; Pierre Lavertu; Rod Rezaee; Shawn Li; Nicole Fowler; Theodoros N Teknos; Quintin Pan Journal: JCO Oncol Pract Date: 2021-05
Authors: Siddharth Sheth; Douglas R Farquhar; Nicholas R Lenze; Angela Mazul; Paul Brennan; Devasena Anantharaman; Behnoush Abedi-Ardekani; Jose P Zevallos; D Neil Hayes; F Olshan Journal: Am J Otolaryngol Date: 2020-10-22 Impact factor: 1.808